Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and see broader potential across other bone disorders.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
- Keros Therapeutics Reports Strong Revenue Growth
- Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
- Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
- Keros Therapeutics reports Q3 EPS (18c), consensus (92c)